Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 1, 2007, Pages 89-96

  Ferro, M M ^a   Angelucci, M E M ^a   Anselmo Franci, J A ^b   Canteras, N S ^c   Da Cunha, C ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Faculdade de Odontologia de Ribeirao Preto   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; 6 Hydroxydopamine; Ketamine; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; KETAMINE; MONOAMINE; NEUROTOXIN; OXIDOPAMINE; THIOPENTAL; TYROSINE 3 MONOOXYGENASE; XYLAZINE;

AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; MALE; MAZE TEST; MESENCEPHALON; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA; WISTAR RAT; WORKING MEMORY;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 33846298071     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2007000100012     Document Type: Article

References (22)

1. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302: 819-822.
2. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999; 122 (Pt 8): 1437-1448.
3. Fearnley JM, Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
4. Da Cunha C, Angelucci ME, Canteras NS, Wonnacott S, Takahashi RN. The lesion of the rat substantia nigra pars compacta, dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell Mol Neurobiol 2002; 22: 227-237.
5. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50: 275-331.
6. Da Cunha C, Wietzikoski S, Wietzikoski EC, Miyoshi E, Ferro MM, Anselmo-Franci JA et al. Evidence for the substantia nigra pars compacta as an essential component of a memory system independent of the hippocampal memory system. Neurobiol Learn Mem, 2003; 79: 236-242.
7. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 2005; 148: 78-87.
8. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001; 65: 135-172.
9. National Institutes of Health. Guide for the care and use of laboratory animals. http://www.nap.edu/readingroom/books/labrats. Accessed August 28, 2006.
10. Abercrombie M. Estimation of nuclear population of microtome sections. Anat Rec 1946; 94: 239-247.
11. Tabatabaei A, Perry TL, Hansen S, Krieger C. Partial protective effect of MK-801 on MPTP-induced reduction of striatall dopamine in mice. Neurosci Lett 1992; 141: 192-194.
12. Lange KW, Loschmann PA, Sofic E, Burg M, Horowski R, Kalveram KT, et al. The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 586-592.
13. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fomai F, Corsini GU. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J Neurochem 1992; 59: 733-739.
14. Ossowska K. The role of excitatory amino acids in experimental models of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994; 8: 39-71.
15. Sonsalla PK, Zeevalk GD, Manzino L, Giovanni A, Nicklas WJ. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem 1992; 58: 1979-1982.
16. Finiels-Marlier F, Marini AM, Williams P, Paul SM. The N-methyl-D-aspartate antagonist MK-801 fails to protect dopaminergic neurons from 1-methyl-4-phenylpyridinium toxicity in vitro. J Neurochem 1993; 60: 1968-1971.
17. Michel PP, Agid Y. The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures. Brain Res 1992; 597: 233-240.
18. Schapira AH. Neuroprotection and dopamine agonists. Neurology 2002; 58: S9-S18.
19. Datla KP, Zbarsky V, Dexter DT. Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats. J Neural Transm 2006; 113: 583-591.
20. Hefco V, Yamada K, Hefco A, Hritcu L, Tiron A, Nabeshima T. Role of the mesotelencephalic dopamine system in learning and memory processes in the rat. Eur J Pharmacol 2003; 475: 55-60.
21. Miyoshi E, Wietzikoski S, Camplessei M, Silveira, R, Takahashi RN, Da Cunha C. Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 2002; 58: 41-47.
22. Reichmann H, Summer U, Gerlach M, Riederer P. Pharmacotherapy of idiopathic Parkinson's syndrome with special focus on neuroprotection. Dtsch Z Nervenheilkd 2001; 20: 227-310.